[시장보고서]발기부전 치료제 시장 분석 및 예측 : 유형별, 제품 유형별, 용도별, 최종 사용자별, 기술별, 제형별, 도입 형태별, 구성 요소별, 기기별, 개발 단계별(-2035년)

발기부전 치료제 시장 분석 및 예측 : 유형별, 제품 유형별, 용도별, 최종 사용자별, 기술별, 제형별, 도입 형태별, 구성 요소별, 기기별, 개발 단계별(-2035년)

Erectile Dysfunction Drugs Market Analysis and Forecast to 2035: Type, Product, Application, End User, Technology, Form, Deployment, Component, Device, Stage

상품코드 : 1951859

리서치사 : Global Insight Services

발행일 : 2026년 02월

페이지 정보 : 영문 312 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,750

￦ 7,189,000

PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF, Excel 이용 범위와 동일합니다.

US $ 5,750

￦ 8,702,000

PDF & Excel (Site License)

PDF, Excel 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다.

US $ 6,750

￦ 10,216,000

PDF & Excel (Enterprise License)

PDF, Excel 보고서를 동일 기업의 전 세계 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF, Excel 이용 범위와 동일합니다.

한글목차

샘플 요청 목록에 추가

발기부전 치료제 시장은 2024년 32억 달러로 평가되었고, 2034년까지 84억 달러에 이르고, CAGR은 약 9.7%를 나타낼 것으로 예측됩니다. 발기부전 치료제 시장은 발기부전 치료를 목적으로 한 의약품을 대상으로 혈류 개선과 호르몬 균형 조정에 중점을 둡니다. 이 시장에는 PDE5 억제제, 호르몬 요법 및 대체 의학이 포함됩니다. 생활 습관병 증가 추세와 노인 인구의 확대가 시장 성장을 가속하고 있습니다. 약물 전달 시스템의 혁신과 성 건강에 대한 인식 확대는 시장 역학의 변화에 기여합니다.

발기부전 치료제 시장은 치료 옵션에 대한 인지도와 수용성 향상을 배경으로 견고한 성장을 이루고 있습니다. 경구 약물 부문은 효능과 편의성으로 알려진 포스포디에스테라아제 5형 억제제의 인기에 견인되어 가장 높은 성과를 올리는 하위 부문입니다. 즉각적인 효과와 효과를 제공하는 주사제는 신속한 결과를 추구하는 사람들에게 매력적인 성과 2위의 하위 부문입니다. 프라이버시와 가용성에 대한 선호도가 높아짐에 따라 시판 약물 부문은 주목을 받고 있습니다. 한편, 처방약은 확립된 신뢰성과 입증된 효과를 반영하여 시장을 계속 독점하고 있습니다. 외부 크림 및 경피 흡수 패치와 같은 혁신적인 투여 방법은 대체 투여 경로를 추구하는 개인에게 대응하는 유망한 기회로 부상하고 있습니다. 또한, 개별 유전자 프로파일에 맞춘 치료에 의해 효능을 높여, 부작용을 경감하는 맞춤형 의료의 진전도 볼 수 있습니다. R&D 투자 증가는 새로운 혁신을 촉진하고 시장의 지속적인 성장 가능성을 확고히할 것으로 예측됩니다.

시장 세분화
유형별	PDE5 억제제, 남성호르몬 보충 요법, 프로스타글란딘
제품	경구약, 주사제, 외용약, 음압 발기 보조기, 음경 임플란트
적응증	고혈압성 발기부전, 당뇨병성 발기부전, 심인성 발기부전
최종 사용자	병원, 진료소, 재택치료, 전문 치료 센터
기술	생명공학, 약물유전체학, 나노기술
투약 형태	정제, 캡슐, 젤, 주사제
제공 형태	소매 약국, 온라인 약국, 병원 약국
성분	원료 의약품, 첨가제
의료기기	음압기, 남근 임플란트
단계	임상시험, 상용화 단계, 연구개발

발기부전 치료제 시장은 다양한 제품군이 시장 점유율을 다투는 특징을 가지고 있습니다. 가격 전략은 기업에 따라 다르며 브랜드 힘을 기반으로 프리미엄 가격 설정을 선택하는 기업도 있고, 보다 광범위한 고객층을 획득하기 위해 저렴한 가격에 주력하는 기업도 있습니다. 지속적인 R&D 노력으로 보다 효과적이고 안전한 옵션을 도입하는 것을 목표로 하는 신제품 출시가 빈번히 이루어지고 있습니다. 이 역동적인 상황은 특허 만료와 제네릭 의약품의 등장에 의해 더욱 영향을 받고 경쟁의 구도를 재구성하고 있습니다. 경쟁 구도은 소수의 주요 기업에 의해 지배되고 있지만, 일부 신흥 기업들이 현저한 진보를 이루고 있습니다. 벤치마크 조사는 시장에서의 지위를 강화하기 위한 혁신과 전략적 제휴에 초점을 맞추었습니다. 규제의 영향은 매우 크며, 엄격한 승인 프로세스와 컴플라이언스 요구 사항이 시장 진입과 확대에 달려 있습니다. 북미와 유럽은 규제 체제의 관점에서 여전히 중요하지만, 아시아태평양의 신흥 시장에서는 규제 상황이 변화하는 가운데 지속적인 확장이 예상됩니다. 인구 역학 변화와 의식이 증가함에 따라 시장은 성장의 징조를 보이고 있습니다.

주요 동향과 촉진요인

발기부전 치료제 시장은 몇 가지 주요 동향과 촉진요인에 의해 현저한 성장을 이루고 있습니다. 주목할만한 동향 중 하나는 발기 부전이 일반적인 의료 상태로 받아 들여지면서 사회적 편견이 감소하고 더 많은 개인이 치료를 요구하도록 촉구되고 있습니다. 이 사회적 인식의 변화로 인해 더 많은 환자들이 의료 전문가와 증상에 대해 논의하는 것을 괴롭히고 시장이 확대되고 있습니다. 또 다른 동향은 약물의 제제 기술이 진보하고 지속 시간이 길고 즉각적인 약물이 개발되고 있다는 것입니다. 이러한 혁신은 환자 만족도와 치료 계획 준수를 향상시킵니다. 또한 원격 의료 플랫폼의 상승으로 환자가 처방전이나 진찰을 받기 쉬워지고 발기 부전 치료의 보급 범위가 넓어지고 있습니다. 시장 성장의 요인으로는 노화에 따라 발기부전의 유병률이 상승하는 고령화 사회의 진전을 들 수 있습니다. 또한 의료 서비스 제공업체와 제약 회사의 계발 활동과 교육 캠페인의 강화로 치료 옵션에 대한 일반 인지도가 높아지고 있습니다. 또한 비만과 당뇨병 증가와 같은 생활습관의 변화가 발기부전의 발생률 상승에 기여하고 있어 효과적인 치료법에 대한 수요를 견인하고 있습니다. 이러한 동향과 촉진요인이 지속적으로 진전하는 가운데, 시장은 지속적인 성장이 예상됩니다.

시장 규모 및 예측 : 유형별
- PDE5 억제제
- 남성호르몬 보충 요법
- 프로스타글란딘
시장 규모 및 예측 : 제품별
- 경구약
- 주사제
- 외용약
- 음압 발기 보조기
- 음경 임플란트
시장 규모 및 예측 : 용도별
- 고혈압성 발기부전
- 당뇨병성 발기부전
- 심인성 발기부전
시장 규모 및 예측 : 최종사용자별
- 병원
- 진료소
- 재택치료
- 전문의료센터
시장 규모 및 예측 : 기술별
- 생명공학
- 약물유전체학
- 나노기술
시장 규모 및 예측 : 형태별
- 정제
- 캡슐
- 젤
- 주사제
시장 규모 및 예측 : 전개별
- 소매 약국
- 온라인 약국
- 병원 약국
시장 규모 및 예측 : 구성요소별
- 원료 의약품
- 첨가제
시장 규모 및 예측 : 기기별
- 음압기
- 음경 임플란트
시장 규모 및 예측 : 스테이지별
- 임상시험
- 상용화 단계
- 연구개발

제5장 지역별 분석

북미
- 미국
- 캐나다
- 멕시코
라틴아메리카
- 브라질
- 아르헨티나
- 기타 라틴아메리카
아시아태평양
- 중국
- 인도
- 한국
- 일본
- 호주
- 대만
- 기타 아시아태평양
유럽
- 독일
- 프랑스
- 영국
- 스페인
- 이탈리아
- 기타 유럽
중동 및 아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 남아프리카
- 사하라 이남 아프리카
- 기타 중동 및 아프리카

제6장 시장 전략

수요 및 공급 격차 분석
무역 및 물류상의 제약
가격-비용-마진 추세
시장 침투
소비자 분석
규제 개요

제7장 경쟁 정보

시장 포지셔닝
시장 점유율
경쟁 벤치마킹
주요 기업의 전략

제8장 기업 프로파일

Futura Medical
VIVUS
Hims and Hers Health
Petros Pharmaceuticals
Veru
Aytu Bio Pharma
Marius Pharmaceuticals
Metuchen Pharmaceuticals
TLC Biopharmaceuticals
Seelos Therapeutics
Reckitt Benckiser
Viatris
Pfizer
Eli Lilly
Bayer
Teva Pharmaceutical Industries
Glaxo Smith Kline
Sanofi
Novo Nordisk
Abbott Laboratories

제9장 당사에 대해서

SHW

영문 목차

영문목차

Erectile Dysfunction Drugs Market is anticipated to expand from $3.2 billion in 2024 to $8.4 billion by 2034, growing at a CAGR of approximately 9.7%. The Erectile Dysfunction Drugs Market encompasses pharmaceuticals designed to treat erectile dysfunction, focusing on enhancing blood flow and hormonal balance. This market includes PDE5 inhibitors, hormone therapy, and alternative medications. Rising prevalence of lifestyle-related disorders and increasing geriatric population fuel market growth. Innovations in drug delivery systems and expanding awareness of sexual health contribute to evolving market dynamics.

The Erectile Dysfunction Drugs Market is experiencing robust growth, fueled by increased awareness and acceptance of treatment options. The oral drug segment is the top-performing sub-segment, driven by the popularity of phosphodiesterase type 5 inhibitors, known for their efficacy and convenience. Injectable drugs, offering rapid onset and effectiveness, are the second-highest performing sub-segment, appealing to those seeking immediate results. The over-the-counter segment is gaining traction due to the growing preference for privacy and ease of access. Meanwhile, prescription-based drugs continue to dominate, reflecting their established trust and proven results. Innovative delivery methods, such as topical creams and transdermal patches, are emerging as promising opportunities, catering to individuals seeking alternative routes of administration. The market is also seeing advancements in personalized medicine, with treatments tailored to individual genetic profiles, enhancing efficacy and reducing side effects. Increased R&D investments are expected to drive further innovation, solidifying the market's potential for sustained growth.

Market Segmentation
Type	Phosphodiesterase Type 5 Inhibitors, Testosterone Replacement Therapy, Prostaglandins
Product	Oral Medications, Injectable Drugs, Topical Medications, Vacuum Erection Devices, Penile Implants
Application	Hypertension-Induced ED, Diabetes-Induced ED, Psychological ED
End User	Hospitals, Clinics, Homecare, Specialty Centers
Technology	Biotechnology, Pharmacogenomics, Nanotechnology
Form	Tablets, Capsules, Gels, Injections
Deployment	Retail Pharmacies, Online Pharmacies, Hospital Pharmacies
Component	Active Pharmaceutical Ingredients, Excipients
Device	Vacuum Pumps, Penile Implants
Stage	Clinical Trials, Commercialized, Research and Development

The Erectile Dysfunction Drugs Market is characterized by a diverse array of products, each vying for significant market share. Pricing strategies vary, with some companies opting for premium pricing due to brand reputation, while others focus on affordability to capture a broader customer base. New product launches are frequent, driven by continuous research and development efforts, aiming to introduce more effective and safer options. This dynamic landscape is further influenced by patent expirations and the introduction of generic alternatives, which reshape competitive dynamics. The competitive landscape is dominated by a few key players, with several emerging companies making notable strides. Benchmarking reveals a focus on innovation and strategic partnerships to enhance market positioning. Regulatory influences are profound, with stringent approval processes and compliance requirements dictating market entry and expansion. North America and Europe remain pivotal due to their regulatory frameworks, while emerging markets in Asia-Pacific present lucrative opportunities as regulatory landscapes evolve. The market is poised for growth, driven by demographic shifts and increasing awareness.

Geographical Overview:

The Erectile Dysfunction Drugs Market is witnessing notable growth across various regions, each presenting unique opportunities. North America remains a dominant player, driven by a high prevalence of erectile dysfunction, advanced healthcare infrastructure, and increased awareness about treatment options. The region's focus on innovative drug development and strong healthcare spending further bolsters market growth. Europe follows suit, with a robust pharmaceutical industry and growing awareness campaigns contributing to market expansion. The region's aging population and emphasis on quality healthcare services enhance its market presence. In Asia Pacific, the market is experiencing rapid growth, propelled by rising disposable incomes and increasing healthcare access. Emerging economies like China and India are becoming key growth pockets due to their large patient pools and improving healthcare infrastructure. Latin America and the Middle East & Africa present emerging opportunities. In Latin America, improving healthcare systems and increasing awareness drive demand, while the Middle East & Africa are recognizing the importance of addressing erectile dysfunction as part of broader health initiatives.

The global erectile dysfunction drugs market is navigating a complex landscape of tariffs and geopolitical risks, particularly in Japan, South Korea, China, and Taiwan. These nations are adapting to trade tensions by enhancing pharmaceutical innovation and fostering regional partnerships. Japan and South Korea are increasing investments in R&D to mitigate tariff impacts on imports. China's focus on developing domestic pharmaceutical capabilities is intensifying, while Taiwan leverages its advanced biotech infrastructure to maintain competitiveness. The parent market is experiencing robust growth due to rising demand and demographic shifts, with expectations of continued expansion through 2035. Geopolitical tensions, including Middle East conflicts, could disrupt global supply chains and elevate energy prices, necessitating strategic resilience and diversification within the industry to sustain growth.

Key Trends and Drivers:

The Erectile Dysfunction Drugs Market is experiencing notable growth due to several key trends and drivers. One prominent trend is the increasing acceptance of erectile dysfunction as a common medical condition, which is reducing stigma and encouraging more individuals to seek treatment. This shift in societal perception is expanding the market as more patients are willing to discuss their symptoms with healthcare professionals. Another trend is the advancement in drug formulations, including the development of longer-lasting and faster-acting medications. These innovations are enhancing patient satisfaction and adherence to treatment regimens. Additionally, the rise of telemedicine platforms is making it easier for patients to access prescriptions and consultations, thus broadening the reach of erectile dysfunction treatments. Drivers of market growth include a growing aging population, as erectile dysfunction prevalence increases with age. Moreover, increased awareness and education campaigns by healthcare providers and pharmaceutical companies are informing the public about treatment options. Furthermore, lifestyle changes, such as rising incidences of obesity and diabetes, are contributing to higher rates of erectile dysfunction, thereby driving demand for effective therapeutic solutions. The market is poised for sustained growth as these trends and drivers continue to evolve.

Research Scope:

Estimates and forecasts the overall market size across type, application, and region.
Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

1 Executive Summary

1.1 Market Size and Forecast
1.2 Market Overview
1.3 Market Snapshot
1.4 Regional Snapshot
1.5 Strategic Recommendations
1.6 Analyst Notes

2 Market Highlights

2.1 Key Market Highlights by Type
2.2 Key Market Highlights by Product
2.3 Key Market Highlights by Application
2.4 Key Market Highlights by End User
2.5 Key Market Highlights by Technology
2.6 Key Market Highlights by Form
2.7 Key Market Highlights by Deployment
2.8 Key Market Highlights by Component
2.9 Key Market Highlights by Device
2.10 Key Market Highlights by Stage

3 Market Dynamics

3.1 Macroeconomic Analysis
3.2 Market Trends
3.3 Market Drivers
3.4 Market Opportunities
3.5 Market Restraints
3.6 CAGR Growth Analysis
3.7 Impact Analysis
3.8 Emerging Markets
3.9 Technology Roadmap
3.10 Strategic Frameworks
- 3.10.1 PORTER's 5 Forces Model
- 3.10.2 ANSOFF Matrix
- 3.10.3 4P's Model
- 3.10.4 PESTEL Analysis

4 Segment Analysis

4.1 Market Size & Forecast by Type (2020-2035)
- 4.1.1 Phosphodiesterase Type 5 Inhibitors
- 4.1.2 Testosterone Replacement Therapy
- 4.1.3 Prostaglandins
4.2 Market Size & Forecast by Product (2020-2035)
- 4.2.1 Oral Medications
- 4.2.2 Injectable Drugs
- 4.2.3 Topical Medications
- 4.2.4 Vacuum Erection Devices
- 4.2.5 Penile Implants
4.3 Market Size & Forecast by Application (2020-2035)
- 4.3.1 Hypertension-Induced ED
- 4.3.2 Diabetes-Induced ED
- 4.3.3 Psychological ED
4.4 Market Size & Forecast by End User (2020-2035)
- 4.4.1 Hospitals
- 4.4.2 Clinics
- 4.4.3 Homecare
- 4.4.4 Specialty Centers
4.5 Market Size & Forecast by Technology (2020-2035)
- 4.5.1 Biotechnology
- 4.5.2 Pharmacogenomics
- 4.5.3 Nanotechnology
4.6 Market Size & Forecast by Form (2020-2035)
- 4.6.1 Tablets
- 4.6.2 Capsules
- 4.6.3 Gels
- 4.6.4 Injections
4.7 Market Size & Forecast by Deployment (2020-2035)
- 4.7.1 Retail Pharmacies
- 4.7.2 Online Pharmacies
- 4.7.3 Hospital Pharmacies
4.8 Market Size & Forecast by Component (2020-2035)
- 4.8.1 Active Pharmaceutical Ingredients
- 4.8.2 Excipients
4.9 Market Size & Forecast by Device (2020-2035)
- 4.9.1 Vacuum Pumps
- 4.9.2 Penile Implants
4.10 Market Size & Forecast by Stage (2020-2035)
- 4.10.1 Clinical Trials
- 4.10.2 Commercialized
- 4.10.3 Research and Development

5 Regional Analysis

5.1 Global Market Overview
5.2 North America Market Size (2020-2035)
- 5.2.1 United States
  - 5.2.1.1 Type
  - 5.2.1.2 Product
  - 5.2.1.3 Application
  - 5.2.1.4 End User
  - 5.2.1.5 Technology
  - 5.2.1.6 Form
  - 5.2.1.7 Deployment
  - 5.2.1.8 Component
  - 5.2.1.9 Device
  - 5.2.1.10 Stage
- 5.2.2 Canada
  - 5.2.2.1 Type
  - 5.2.2.2 Product
  - 5.2.2.3 Application
  - 5.2.2.4 End User
  - 5.2.2.5 Technology
  - 5.2.2.6 Form
  - 5.2.2.7 Deployment
  - 5.2.2.8 Component
  - 5.2.2.9 Device
  - 5.2.2.10 Stage
- 5.2.3 Mexico
  - 5.2.3.1 Type
  - 5.2.3.2 Product
  - 5.2.3.3 Application
  - 5.2.3.4 End User
  - 5.2.3.5 Technology
  - 5.2.3.6 Form
  - 5.2.3.7 Deployment
  - 5.2.3.8 Component
  - 5.2.3.9 Device
  - 5.2.3.10 Stage
5.3 Latin America Market Size (2020-2035)
- 5.3.1 Brazil
  - 5.3.1.1 Type
  - 5.3.1.2 Product
  - 5.3.1.3 Application
  - 5.3.1.4 End User
  - 5.3.1.5 Technology
  - 5.3.1.6 Form
  - 5.3.1.7 Deployment
  - 5.3.1.8 Component
  - 5.3.1.9 Device
  - 5.3.1.10 Stage
- 5.3.2 Argentina
  - 5.3.2.1 Type
  - 5.3.2.2 Product
  - 5.3.2.3 Application
  - 5.3.2.4 End User
  - 5.3.2.5 Technology
  - 5.3.2.6 Form
  - 5.3.2.7 Deployment
  - 5.3.2.8 Component
  - 5.3.2.9 Device
  - 5.3.2.10 Stage
- 5.3.3 Rest of Latin America
  - 5.3.3.1 Type
  - 5.3.3.2 Product
  - 5.3.3.3 Application
  - 5.3.3.4 End User
  - 5.3.3.5 Technology
  - 5.3.3.6 Form
  - 5.3.3.7 Deployment
  - 5.3.3.8 Component
  - 5.3.3.9 Device
  - 5.3.3.10 Stage
5.4 Asia-Pacific Market Size (2020-2035)
- 5.4.1 China
  - 5.4.1.1 Type
  - 5.4.1.2 Product
  - 5.4.1.3 Application
  - 5.4.1.4 End User
  - 5.4.1.5 Technology
  - 5.4.1.6 Form
  - 5.4.1.7 Deployment
  - 5.4.1.8 Component
  - 5.4.1.9 Device
  - 5.4.1.10 Stage
- 5.4.2 India
  - 5.4.2.1 Type
  - 5.4.2.2 Product
  - 5.4.2.3 Application
  - 5.4.2.4 End User
  - 5.4.2.5 Technology
  - 5.4.2.6 Form
  - 5.4.2.7 Deployment
  - 5.4.2.8 Component
  - 5.4.2.9 Device
  - 5.4.2.10 Stage
- 5.4.3 South Korea
  - 5.4.3.1 Type
  - 5.4.3.2 Product
  - 5.4.3.3 Application
  - 5.4.3.4 End User
  - 5.4.3.5 Technology
  - 5.4.3.6 Form
  - 5.4.3.7 Deployment
  - 5.4.3.8 Component
  - 5.4.3.9 Device
  - 5.4.3.10 Stage
- 5.4.4 Japan
  - 5.4.4.1 Type
  - 5.4.4.2 Product
  - 5.4.4.3 Application
  - 5.4.4.4 End User
  - 5.4.4.5 Technology
  - 5.4.4.6 Form
  - 5.4.4.7 Deployment
  - 5.4.4.8 Component
  - 5.4.4.9 Device
  - 5.4.4.10 Stage
- 5.4.5 Australia
  - 5.4.5.1 Type
  - 5.4.5.2 Product
  - 5.4.5.3 Application
  - 5.4.5.4 End User
  - 5.4.5.5 Technology
  - 5.4.5.6 Form
  - 5.4.5.7 Deployment
  - 5.4.5.8 Component
  - 5.4.5.9 Device
  - 5.4.5.10 Stage
- 5.4.6 Taiwan
  - 5.4.6.1 Type
  - 5.4.6.2 Product
  - 5.4.6.3 Application
  - 5.4.6.4 End User
  - 5.4.6.5 Technology
  - 5.4.6.6 Form
  - 5.4.6.7 Deployment
  - 5.4.6.8 Component
  - 5.4.6.9 Device
  - 5.4.6.10 Stage
- 5.4.7 Rest of APAC
  - 5.4.7.1 Type
  - 5.4.7.2 Product
  - 5.4.7.3 Application
  - 5.4.7.4 End User
  - 5.4.7.5 Technology
  - 5.4.7.6 Form
  - 5.4.7.7 Deployment
  - 5.4.7.8 Component
  - 5.4.7.9 Device
  - 5.4.7.10 Stage
5.5 Europe Market Size (2020-2035)
- 5.5.1 Germany
  - 5.5.1.1 Type
  - 5.5.1.2 Product
  - 5.5.1.3 Application
  - 5.5.1.4 End User
  - 5.5.1.5 Technology
  - 5.5.1.6 Form
  - 5.5.1.7 Deployment
  - 5.5.1.8 Component
  - 5.5.1.9 Device
  - 5.5.1.10 Stage
- 5.5.2 France
  - 5.5.2.1 Type
  - 5.5.2.2 Product
  - 5.5.2.3 Application
  - 5.5.2.4 End User
  - 5.5.2.5 Technology
  - 5.5.2.6 Form
  - 5.5.2.7 Deployment
  - 5.5.2.8 Component
  - 5.5.2.9 Device
  - 5.5.2.10 Stage
- 5.5.3 United Kingdom
  - 5.5.3.1 Type
  - 5.5.3.2 Product
  - 5.5.3.3 Application
  - 5.5.3.4 End User
  - 5.5.3.5 Technology
  - 5.5.3.6 Form
  - 5.5.3.7 Deployment
  - 5.5.3.8 Component
  - 5.5.3.9 Device
  - 5.5.3.10 Stage
- 5.5.4 Spain
  - 5.5.4.1 Type
  - 5.5.4.2 Product
  - 5.5.4.3 Application
  - 5.5.4.4 End User
  - 5.5.4.5 Technology
  - 5.5.4.6 Form
  - 5.5.4.7 Deployment
  - 5.5.4.8 Component
  - 5.5.4.9 Device
  - 5.5.4.10 Stage
- 5.5.5 Italy
  - 5.5.5.1 Type
  - 5.5.5.2 Product
  - 5.5.5.3 Application
  - 5.5.5.4 End User
  - 5.5.5.5 Technology
  - 5.5.5.6 Form
  - 5.5.5.7 Deployment
  - 5.5.5.8 Component
  - 5.5.5.9 Device
  - 5.5.5.10 Stage
- 5.5.6 Rest of Europe
  - 5.5.6.1 Type
  - 5.5.6.2 Product
  - 5.5.6.3 Application
  - 5.5.6.4 End User
  - 5.5.6.5 Technology
  - 5.5.6.6 Form
  - 5.5.6.7 Deployment
  - 5.5.6.8 Component
  - 5.5.6.9 Device
  - 5.5.6.10 Stage
5.6 Middle East & Africa Market Size (2020-2035)
- 5.6.1 Saudi Arabia
  - 5.6.1.1 Type
  - 5.6.1.2 Product
  - 5.6.1.3 Application
  - 5.6.1.4 End User
  - 5.6.1.5 Technology
  - 5.6.1.6 Form
  - 5.6.1.7 Deployment
  - 5.6.1.8 Component
  - 5.6.1.9 Device
  - 5.6.1.10 Stage
- 5.6.2 United Arab Emirates
  - 5.6.2.1 Type
  - 5.6.2.2 Product
  - 5.6.2.3 Application
  - 5.6.2.4 End User
  - 5.6.2.5 Technology
  - 5.6.2.6 Form
  - 5.6.2.7 Deployment
  - 5.6.2.8 Component
  - 5.6.2.9 Device
  - 5.6.2.10 Stage
- 5.6.3 South Africa
  - 5.6.3.1 Type
  - 5.6.3.2 Product
  - 5.6.3.3 Application
  - 5.6.3.4 End User
  - 5.6.3.5 Technology
  - 5.6.3.6 Form
  - 5.6.3.7 Deployment
  - 5.6.3.8 Component
  - 5.6.3.9 Device
  - 5.6.3.10 Stage
- 5.6.4 Sub-Saharan Africa
  - 5.6.4.1 Type
  - 5.6.4.2 Product
  - 5.6.4.3 Application
  - 5.6.4.4 End User
  - 5.6.4.5 Technology
  - 5.6.4.6 Form
  - 5.6.4.7 Deployment
  - 5.6.4.8 Component
  - 5.6.4.9 Device
  - 5.6.4.10 Stage
- 5.6.5 Rest of MEA
  - 5.6.5.1 Type
  - 5.6.5.2 Product
  - 5.6.5.3 Application
  - 5.6.5.4 End User
  - 5.6.5.5 Technology
  - 5.6.5.6 Form
  - 5.6.5.7 Deployment
  - 5.6.5.8 Component
  - 5.6.5.9 Device
  - 5.6.5.10 Stage

6 Market Strategy

6.1 Demand-Supply Gap Analysis
6.2 Trade & Logistics Constraints
6.3 Price-Cost-Margin Trends
6.4 Market Penetration
6.5 Consumer Analysis
6.6 Regulatory Snapshot

7 Competitive Intelligence

7.1 Market Positioning
7.2 Market Share
7.3 Competition Benchmarking
7.4 Top Company Strategies

8 Company Profiles

8.1 Futura Medical
- 8.1.1 Overview
- 8.1.2 Product Summary
- 8.1.3 Financial Performance
- 8.1.4 SWOT Analysis
8.2 VIVUS
- 8.2.1 Overview
- 8.2.2 Product Summary
- 8.2.3 Financial Performance
- 8.2.4 SWOT Analysis
8.3 Hims and Hers Health
- 8.3.1 Overview
- 8.3.2 Product Summary
- 8.3.3 Financial Performance
- 8.3.4 SWOT Analysis
8.4 Petros Pharmaceuticals
- 8.4.1 Overview
- 8.4.2 Product Summary
- 8.4.3 Financial Performance
- 8.4.4 SWOT Analysis
8.5 Veru
- 8.5.1 Overview
- 8.5.2 Product Summary
- 8.5.3 Financial Performance
- 8.5.4 SWOT Analysis
8.6 Aytu Bio Pharma
- 8.6.1 Overview
- 8.6.2 Product Summary
- 8.6.3 Financial Performance
- 8.6.4 SWOT Analysis
8.7 Marius Pharmaceuticals
- 8.7.1 Overview
- 8.7.2 Product Summary
- 8.7.3 Financial Performance
- 8.7.4 SWOT Analysis
8.8 Metuchen Pharmaceuticals
- 8.8.1 Overview
- 8.8.2 Product Summary
- 8.8.3 Financial Performance
- 8.8.4 SWOT Analysis
8.9 TLC Biopharmaceuticals
- 8.9.1 Overview
- 8.9.2 Product Summary
- 8.9.3 Financial Performance
- 8.9.4 SWOT Analysis
8.10 Seelos Therapeutics
- 8.10.1 Overview
- 8.10.2 Product Summary
- 8.10.3 Financial Performance
- 8.10.4 SWOT Analysis
8.11 Reckitt Benckiser
- 8.11.1 Overview
- 8.11.2 Product Summary
- 8.11.3 Financial Performance
- 8.11.4 SWOT Analysis
8.12 Viatris
- 8.12.1 Overview
- 8.12.2 Product Summary
- 8.12.3 Financial Performance
- 8.12.4 SWOT Analysis
8.13 Pfizer
- 8.13.1 Overview
- 8.13.2 Product Summary
- 8.13.3 Financial Performance
- 8.13.4 SWOT Analysis
8.14 Eli Lilly
- 8.14.1 Overview
- 8.14.2 Product Summary
- 8.14.3 Financial Performance
- 8.14.4 SWOT Analysis
8.15 Bayer
- 8.15.1 Overview
- 8.15.2 Product Summary
- 8.15.3 Financial Performance
- 8.15.4 SWOT Analysis
8.16 Teva Pharmaceutical Industries
- 8.16.1 Overview
- 8.16.2 Product Summary
- 8.16.3 Financial Performance
- 8.16.4 SWOT Analysis
8.17 Glaxo Smith Kline
- 8.17.1 Overview
- 8.17.2 Product Summary
- 8.17.3 Financial Performance
- 8.17.4 SWOT Analysis
8.18 Sanofi
- 8.18.1 Overview
- 8.18.2 Product Summary
- 8.18.3 Financial Performance
- 8.18.4 SWOT Analysis
8.19 Novo Nordisk
- 8.19.1 Overview
- 8.19.2 Product Summary
- 8.19.3 Financial Performance
- 8.19.4 SWOT Analysis
8.20 Abbott Laboratories
- 8.20.1 Overview
- 8.20.2 Product Summary
- 8.20.3 Financial Performance
- 8.20.4 SWOT Analysis

9 About Us

9.1 About Us
9.2 Research Methodology
9.3 Research Workflow
9.4 Consulting Services
9.5 Our Clients
9.6 Client Testimonials
9.7 Contact Us